Literature DB >> 17597809

Assessment of cellular origin and EBV status in a PTLD after double cord blood transplantation.

G Reddiconto, P Chiusolo, A Fiorini, G Farina, L Laurenti, M Martini, S Marchetti, G Fadda, G Leone, S Sica.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17597809     DOI: 10.1038/sj.leu.2404818

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  6 in total

Review 1.  Post-transplantation lymphoproliferative disorder after haematopoietic stem cell transplantation.

Authors:  Francesco Pegoraro; Claudio Favre
Journal:  Ann Hematol       Date:  2021-02-06       Impact factor: 3.673

2.  Prospective evaluation of epstein-barr virus reactivation after stem cell transplantation: association with monoclonal gammopathy.

Authors:  Patrizia Chiusolo; Elisabetta Metafuni; Paola Cattani; Nicola Piccirillo; Rosaria Santangelo; Stefania Manzara; Silvia Bellesi; Teresa De Michele; Giuseppe Leone; Simona Sica
Journal:  J Clin Immunol       Date:  2010-08-25       Impact factor: 8.317

Review 3.  EBV-induced post transplant lymphoproliferative disorders: a persisting challenge in allogeneic hematopoetic SCT.

Authors:  L Rasche; M Kapp; H Einsele; S Mielke
Journal:  Bone Marrow Transplant       Date:  2013-07-08       Impact factor: 5.483

4.  Epstein-barr virus related lymphoproliferations after stem cell transplantation.

Authors:  Simona Sica; Elisabetta Metafuni; Silvia Bellesi; Patrizia Chiusolo
Journal:  Mediterr J Hematol Infect Dis       Date:  2009-12-14       Impact factor: 2.576

Review 5.  Human cord blood-derived viral pathogens as the potential threats to the hematopoietic stem cell transplantation safety: A mini review.

Authors:  Ali Noroozi-Aghideh; Maryam Kheirandish
Journal:  World J Stem Cells       Date:  2019-02-26       Impact factor: 5.326

Review 6.  Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disorders after Hematopoietic Stem Cell Transplantation: Pathogenesis, Risk Factors and Clinical Outcomes.

Authors:  Ayumi Fujimoto; Ritsuro Suzuki
Journal:  Cancers (Basel)       Date:  2020-02-01       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.